Sep 02, 2021 8:59am EDT Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives
Aug 30, 2021 8:59am EDT FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas
Aug 19, 2021 8:50am EDT Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
Aug 16, 2021 8:20am EDT Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
Aug 11, 2021 8:21am EDT FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Jul 29, 2021 4:01pm EDT Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Jul 27, 2021 8:00am EDT Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
Jul 22, 2021 4:08pm EDT Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
Jul 20, 2021 7:00am EDT Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
May 03, 2021 4:32pm EDT Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
